Clinical Trials and Research News Weekly Roundup | S2 E13

Mar 23, 2020 | Digital Media, Video, Weekly Roundup

Youtube TrialSite News Weekly Roundup

This week, we start our roundup with the story that’s on many folks minds around the globe right now, Covid-19, or the coronavirus.

  • Sanofi Pasteur Collaborates with U.S. HHS on Potential COVID-19 Vaccine that could be Produced at PA Site.
  • INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine.
  • Israel’s Influential Institute for Biological Research Dedicates One-Third of Scientists to COVID-19 Vaccine.
  • The Implication of the Seattle Flu Study & COVID-19 Testing Controversy.
  • Texas Biomedical Research Institute Pursues a COVID-19 Vaccine—It Will Take Time. Emory University NIH-based VTEU Activated for Global COVID-19 Clinical Trials.
  • University of Miami-Originated IP the Basis for Prospective COVID-19 Vaccine.
  • White House Deal Making Moves into Biotech with a Recent Bid to Secure Exclusive Rights to COVID-19 Vaccine from Germany.
  • Wuhan Institute of Virology (China) Sought to Patent Gilead’s Remdesivir.
  • Kaiser Permanente Washington Health Research Institute Doses First Patient for COVID-19 Vaccine with Moderna’s mRNA-1273.
  • Launch of the World’s First Artificial Pancreas App Developed at University of Cambridge.
  • Takeda’s TOURMALINE-MM2 Trial Misses Endpoints in Newly Diagnosed Multiple Myeloma Patients.
  • OptumCare Cancer Care Opens New Clinical Investigational Site in Las Vegas to Meet Growing Care Option Demands.
  • Yale-based Research in Landmark Study that May Lead to First FDA-Approved Traditional Chinese Medication for Liver Cancer.
  • Weill Cornell Medicine-Qatar Probes Anti-Cancer Properties of Metformin & 2-deoxyglucose in Lab & Mice Models.
  • Acceleron Discontinues Development of ACE-083 for Charcot-Marie-Tooth Disease Following Phase 2 Failure.
  • FDA Places Partial Clinical Hold on Unum Therapeutics Phase I Trial for non-Hodgkin Lymphoma Due to Safety Concern.
  • Innovative UNC-based Public-Private HIV Investigative Group Secures $20m & Continues its Leading ‘Induce & Reduce’ Strategy.

0 Comments

Pin It on Pinterest